Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia
ABSTRACT: Introduction: Acute coronary syndrome is one of the most frequent medical emergencies in developing countries.Objective: To determine, from the perspective of the Colombian health system, the cost-effectiveness of ticagrelor compared to clopidogrel for the treatment of patients with acute...
- Autores:
-
Mejía Mejía, Aurelio
Senior, Juan Manuel
Ceballos González, Mateo
Atehortúa Becerra, Sara Catalina
Toro, Juan Manuel
Saldarriaga, Clara
Mejía, María Elena
Ramírez, Carolina
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2015
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/31708
- Acceso en línea:
- https://hdl.handle.net/10495/31708
- Palabra clave:
- Costos y Análisis de Costo
Costs and Cost Analysis
Economía médica
Economics, Medical
Estudios de Evaluación como Asunto
Evaluation Studies as Topic
Síndrome coronario agudo
Acute Coronary Syndrome
Economía de la salud
Health economics
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by-nc-nd/2.5/co/
id |
UDEA2_e02e1b717dea8d13efc1ff40b51b296e |
---|---|
oai_identifier_str |
oai:bibliotecadigital.udea.edu.co:10495/31708 |
network_acronym_str |
UDEA2 |
network_name_str |
Repositorio UdeA |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia |
dc.title.alternative.spa.fl_str_mv |
Análisis de costo-efectividad del ticagrelor en comparación con el clopidogrel para el tratamiento de pacientes con síndrome coronario agudo en Colombia |
title |
Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia |
spellingShingle |
Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia Costos y Análisis de Costo Costs and Cost Analysis Economía médica Economics, Medical Estudios de Evaluación como Asunto Evaluation Studies as Topic Síndrome coronario agudo Acute Coronary Syndrome Economía de la salud Health economics |
title_short |
Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia |
title_full |
Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia |
title_fullStr |
Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia |
title_full_unstemmed |
Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia |
title_sort |
Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in Colombia |
dc.creator.fl_str_mv |
Mejía Mejía, Aurelio Senior, Juan Manuel Ceballos González, Mateo Atehortúa Becerra, Sara Catalina Toro, Juan Manuel Saldarriaga, Clara Mejía, María Elena Ramírez, Carolina |
dc.contributor.author.none.fl_str_mv |
Mejía Mejía, Aurelio Senior, Juan Manuel Ceballos González, Mateo Atehortúa Becerra, Sara Catalina Toro, Juan Manuel Saldarriaga, Clara Mejía, María Elena Ramírez, Carolina |
dc.subject.decs.none.fl_str_mv |
Costos y Análisis de Costo Costs and Cost Analysis Economía médica Economics, Medical Estudios de Evaluación como Asunto Evaluation Studies as Topic Síndrome coronario agudo Acute Coronary Syndrome |
topic |
Costos y Análisis de Costo Costs and Cost Analysis Economía médica Economics, Medical Estudios de Evaluación como Asunto Evaluation Studies as Topic Síndrome coronario agudo Acute Coronary Syndrome Economía de la salud Health economics |
dc.subject.unesco.none.fl_str_mv |
Economía de la salud Health economics |
description |
ABSTRACT: Introduction: Acute coronary syndrome is one of the most frequent medical emergencies in developing countries.Objective: To determine, from the perspective of the Colombian health system, the cost-effectiveness of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome. Materials and methods: We conducted a cost-effectiveness analysis from the perspective of the Colombian health system comparing ticagrelor and clopidogrel for the treatment of patients with acute coronary syndrome. To estimate the expected costs and outcomes, a Markov model was constructed in which patients could remain stable without experiencing new cardiovascular events, suffer from a new event, or die. For the baseline case, a 10-year time horizon and a discount ratio of 3% for costs and benefits were adopted. The transition probabilities were extracted from the PLATO (Platelet Inhibition and Patient Outcomes) clinical trial. Vital statistics were drawn from the Departmento Administrativo Nacional de Estadística (DANE) and additional information from Colombian patients included in the Access registry. To identify and measure resource use, a standard case was built by consulting guidelines and protocols. Unit costs were obtained from Colombian rate lists. A probabilistic sensitivity analysis was conducted in which costs were represented by a triangular distribution, and the effectiveness through a beta distribution.Results: In the base case, the additional cost per quality-adjusted life-year gained with ticagrelor was COP$ 28,411,503. The results were sensitive to changes in the time horizon and the unit cost of clopidogrel. For a willingness-to-pay equivalent to three times the Colombian per capita gross domestic product, the probability of ticagrelor being cost-effective was 75%. Conclusions: Ticagrelor is a cost-effective strategy for the treatment of patients with acute coronary syndrome in Colombia |
publishDate |
2015 |
dc.date.issued.none.fl_str_mv |
2015 |
dc.date.accessioned.none.fl_str_mv |
2022-11-02T19:10:15Z |
dc.date.available.none.fl_str_mv |
2022-11-02T19:10:15Z |
dc.type.spa.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.hasversion.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/CJournalArticle |
dc.type.local.spa.fl_str_mv |
Artículo de revista |
format |
http://purl.org/coar/resource_type/c_6501 |
status_str |
publishedVersion |
dc.identifier.issn.none.fl_str_mv |
0120-4157 |
dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/10495/31708 |
dc.identifier.doi.none.fl_str_mv |
10.7705/biomedica.v35i4.2620 |
dc.identifier.eissn.none.fl_str_mv |
2590-7379 |
identifier_str_mv |
0120-4157 10.7705/biomedica.v35i4.2620 2590-7379 |
url |
https://hdl.handle.net/10495/31708 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.rights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ |
dc.rights.accessrights.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.creativecommons.spa.fl_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/ |
dc.format.mimetype.spa.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Instituto Nacional de Salud |
dc.publisher.group.spa.fl_str_mv |
Economía de la Salud |
institution |
Universidad de Antioquia |
bitstream.url.fl_str_mv |
https://bibliotecadigital.udea.edu.co/bitstream/10495/31708/1/MejiaAurelio_2015_CostEffectivenessAnalysis.pdf https://bibliotecadigital.udea.edu.co/bitstream/10495/31708/2/license_rdf https://bibliotecadigital.udea.edu.co/bitstream/10495/31708/3/license.txt |
bitstream.checksum.fl_str_mv |
6fbad113b8b3f89b91412cca34d6b044 b88b088d9957e670ce3b3fbe2eedbc13 8a4605be74aa9ea9d79846c1fba20a33 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Institucional Universidad de Antioquia |
repository.mail.fl_str_mv |
andres.perez@udea.edu.co |
_version_ |
1812173140981186560 |
spelling |
Mejía Mejía, AurelioSenior, Juan ManuelCeballos González, MateoAtehortúa Becerra, Sara CatalinaToro, Juan ManuelSaldarriaga, ClaraMejía, María ElenaRamírez, Carolina2022-11-02T19:10:15Z2022-11-02T19:10:15Z20150120-4157https://hdl.handle.net/10495/3170810.7705/biomedica.v35i4.26202590-7379ABSTRACT: Introduction: Acute coronary syndrome is one of the most frequent medical emergencies in developing countries.Objective: To determine, from the perspective of the Colombian health system, the cost-effectiveness of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome. Materials and methods: We conducted a cost-effectiveness analysis from the perspective of the Colombian health system comparing ticagrelor and clopidogrel for the treatment of patients with acute coronary syndrome. To estimate the expected costs and outcomes, a Markov model was constructed in which patients could remain stable without experiencing new cardiovascular events, suffer from a new event, or die. For the baseline case, a 10-year time horizon and a discount ratio of 3% for costs and benefits were adopted. The transition probabilities were extracted from the PLATO (Platelet Inhibition and Patient Outcomes) clinical trial. Vital statistics were drawn from the Departmento Administrativo Nacional de Estadística (DANE) and additional information from Colombian patients included in the Access registry. To identify and measure resource use, a standard case was built by consulting guidelines and protocols. Unit costs were obtained from Colombian rate lists. A probabilistic sensitivity analysis was conducted in which costs were represented by a triangular distribution, and the effectiveness through a beta distribution.Results: In the base case, the additional cost per quality-adjusted life-year gained with ticagrelor was COP$ 28,411,503. The results were sensitive to changes in the time horizon and the unit cost of clopidogrel. For a willingness-to-pay equivalent to three times the Colombian per capita gross domestic product, the probability of ticagrelor being cost-effective was 75%. Conclusions: Ticagrelor is a cost-effective strategy for the treatment of patients with acute coronary syndrome in ColombiaRESUMEN: Introducción. El síndrome coronario agudo es una de las emergencias médicas más frecuentes en los países en desarrollo.Objetivo. Determinar, desde la perspectiva del sistema de salud colombiano, la relación de costo-efectividad del ticagrelor comparado con el clopidogrel para el tratamiento de pacientes con síndrome coronario agudo. Materiales y métodos. Se hizo un análisis de costo-efectividad desde la perspectiva del sistema de salud colombiano, comparando el ticagrelor y el clopidogrel para el tratamiento de pacientes con síndrome coronario agudo. Para estimar los costos y resultados esperados de las dos alternativas, se construyó un modelo de Markov en el cual los pacientes podían permanecer estables sin experimentar nuevos eventos cardiovasculares, sufrir de un nuevo evento coronario o morir. Para el caso de base, se adoptó un horizonte temporal de 10 años y una tasa de descuento de 3 % para los costos y beneficios. Las probabilidades de transición se extrajeron del estudio Platelet Inhibition and Patient Outcomes, PLATO. Las estadísticas vitales se consultaron en informes del Departamento Administrativo Nacional de Estadística (DANE) y los parámetros adicionales del modelo se basaron en la información de los pacientes colombianos incluidos en el registro en Access. Para identificar y medir el uso de recursos, se construyó un caso estándar a partir de guías y protocolos. Los costos unitarios se obtuvieron de manuales tarifarios colombianos. Se hizo un análisis de sensibilidad probabilístico en el que los costos se representaron por una distribución triangular y, las probabilidades de transición, mediante una distribución beta.Resultados. En el caso de base, el costo adicional por años de vida ajustados por calidad ganados con el ticagrelor fue de COP$ 28’411.503. Los resultados fueron sensibles a los cambios en el horizonte temporal y al costo unitario del clopidogrel. Para un umbral de costo-efectividad equivalente a tres veces el producto interno bruto per cápita de Colombia, la probabilidad de que el ticagrelor fuera costo-efectivo fue de 75 %.Conclusiones. El ticagrelor es una estrategia costo-efectiva para el tratamiento de los pacientes con síndrome coronario agudo en Colombia.application/pdfengInstituto Nacional de SaludEconomía de la Saludinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1http://purl.org/redcol/resource_type/CJournalArticleArtículo de revistahttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/http://purl.org/coar/access_right/c_abf2https://creativecommons.org/licenses/by/4.0/Cost-Effectiveness Analysis of Ticagrelor Compared to Clopidogrel for the Treatment of Patients With Acute Coronary Syndrome in ColombiaAnálisis de costo-efectividad del ticagrelor en comparación con el clopidogrel para el tratamiento de pacientes con síndrome coronario agudo en ColombiaCostos y Análisis de CostoCosts and Cost AnalysisEconomía médicaEconomics, MedicalEstudios de Evaluación como AsuntoEvaluation Studies as TopicSíndrome coronario agudoAcute Coronary SyndromeEconomía de la saludHealth economicsRevista Biomédica531540354ORIGINALMejiaAurelio_2015_CostEffectivenessAnalysis.pdfMejiaAurelio_2015_CostEffectivenessAnalysis.pdfArticulo de revistaapplication/pdf217355https://bibliotecadigital.udea.edu.co/bitstream/10495/31708/1/MejiaAurelio_2015_CostEffectivenessAnalysis.pdf6fbad113b8b3f89b91412cca34d6b044MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8823https://bibliotecadigital.udea.edu.co/bitstream/10495/31708/2/license_rdfb88b088d9957e670ce3b3fbe2eedbc13MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstream/10495/31708/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD5310495/31708oai:bibliotecadigital.udea.edu.co:10495/317082022-11-02 14:11:32.992Repositorio Institucional Universidad de Antioquiaandres.perez@udea.edu.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 |